Open an account

Drugs Made In America Acquisition

DMAAR · NASDAQ

$0.10+$0.0045 (+4.71%)TodayMarket closed ·
No price history for this range.

About DMAAR

Drugs Made In America Acquisition Corp. is a blank check company, which engages in the provision of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company is headquartered in Fort Lauderdale, Florida. The company went IPO on 2025-01-28. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The firm intends to focus its search for businesses in the pharmaceutical industry. The firm has neither engaged in any operations nor generated any revenues.

Employees
0
Headquarters
Fort Lauderdale, Florida
Listed
Jan 28, 2025
Sector
N/A
Industry
N/A
Website
dmaacorp.com

DMAAR key statistics

Market cap
264.01M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.58K
Volume
10.62K
Open price
$0.0999
High today
$0.10
Low today
$0.0998
52 Week high
$0.21
52 Week low
$0.04

Drugs Made In America Acquisition (DMAAR) at a glance

Drugs Made In America Acquisition (DMAAR) last traded at $0.10, with a market cap of 264.01M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0998 and $0.10. The current price is 0.2% above the day's low and 0.0% below its high.

Volume so far is 10.62K shares, in line with the average of 9.58K shares a day.

Over the past year Drugs Made In America Acquisition has ranged from $0.04 to $0.21, and now sits 35% of the way up that range.

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.